Tendinopathy First-Line Treatment Decision Framework

What Is Tendinopathy and Why Does the Diagnosis Change Treatment?

Tendinopathy is not a single disease. It describes a spectrum of painful tendon pathology ranging from reactive tendinopathy (acute cellular response to overload) to degenerative tendinopathy (disorganized collagen, neovascularization, failed healing). Getting that distinction right before prescribing treatment matters because a reactive tendon needs relative rest while a degenerative tendon needs progressive load.

Histopathology Drives the Treatment Rationale

Classic tendinopathy histology shows collagen disorganization, increased proteoglycan content, and the near-total absence of inflammatory cells. This finding, replicated across Achilles, patellar, and rotator cuff specimens, is why the term "tendinitis" has been largely retired in the primary literature. A 2010 review by Khan and Scott published in the British Journal of Sports Medicine described the condition as "a failed healing response" rather than a true inflammatory process, which reframes why NSAIDs alone do not resolve chronic cases [1].

Tendon Continuum Model

Cook and Purdam's tendon continuum model, first published in the British Journal of Sports Medicine in 2009, classifies tendons across three stages: reactive, tendon disrepair, and degenerative [2]. This model underpins virtually every modern loading protocol. A stage-1 reactive tendon in a 22-year-old basketball player is managed very differently from a stage-3 degenerative Achilles in a 54-year-old recreational runner. Treatment must match the stage, not just the anatomical location.

Step 1: Load Management as the Foundation of Care

Load management is the single most evidence-supported first-line intervention across all tendinopathy sites. The goal is to reduce provocative load acutely while maintaining tissue stimulus to prevent further deconditioning.

Isometric Exercise in the Reactive Phase

During the reactive phase, isometric contractions (held for 30-45 seconds, 4-5 repetitions, once or twice daily) reduce tendon pain acutely with minimal compressive stress on the tissue. A randomized trial by Rio et al. Published in the British Journal of Sports Medicine (N=29) showed that isometric leg press at 70% of maximum voluntary contraction produced immediate cortical pain inhibition in patellar tendinopathy, with pain reductions of 36-46% on the VAS immediately post-exercise compared to isotonic exercise [3]. These effects persisted for at least 45 minutes.

Eccentric Exercise for Degenerative Tendinopathy

The Alfredson eccentric heel-drop protocol remains the most cited loading program for Achilles tendinopathy. Alfredson's original 1998 trial (N=15) in the American Journal of Sports Medicine showed that 12 weeks of eccentric calf raises (3 sets of 15 repetitions twice daily, progressing with added load) returned all 15 patients to their previous running level versus no improvement in the concentric control group [4]. Subsequent systematic reviews have confirmed this finding. A Cochrane review by Sussmilch-Leitch et al. Found that eccentric exercise reduced pain and improved function compared to wait-and-see approaches, though the quality of evidence remained moderate [5].

For lateral epicondyle tendinopathy (tennis elbow), a 2009 RCT by Stasinopoulos and Stasinopoulos (N=75) in the Journal of Science and Medicine in Sport showed eccentric wrist extensor exercise produced significantly better outcomes than static stretching at 12 weeks (P<0.01) [6].

Step 2: Adjunctive Physical Treatments

When supervised loading alone produces insufficient pain control or when tissue irritability is too high to progress loading, adjunctive physical treatments can be layered in.

Heavy Slow Resistance Training

Heavy slow resistance (HSR) training uses both concentric and eccentric phases at slow tempo (3 seconds each) with heavier loads than classic eccentric protocols. A landmark RCT by Beyer et al. In the American Journal of Sports Medicine (N=58) compared HSR to Alfredson eccentric training for Achilles tendinopathy over 12 weeks and found equivalent improvements in the VISA-A score (Victorian Institute of Sport Assessment-Achilles), but HSR patients reported higher satisfaction and greater tendon structural changes on ultrasound at the 52-week follow-up [7]. For patients who find pure eccentric loading painful or technically difficult, HSR offers a clinically equivalent alternative.

Extracorporeal Shockwave Therapy

Extracorporeal shockwave therapy (ESWT) is a non-invasive mechanical stimulus that accelerates tendon remodeling and inhibits nociceptors. An RCT by Rompe et al. In the American Journal of Sports Medicine (N=68) showed that a combination of eccentric loading plus low-energy ESWT outperformed either treatment alone in mid-portion Achilles tendinopathy at 4 months, with a combined success rate of 85% versus 70% and 60% respectively [8]. ESWT is typically administered in 3 sessions spaced 1 week apart.

Topical and Systemic NSAIDs

Topical diclofenac is preferred over oral NSAIDs for lateral epicondyle tendinopathy to minimize systemic side effects. A Cochrane review by Pattanittum et al. Confirmed short-term benefit for topical NSAIDs in lateral epicondyle pain, noting a Number Needed to Treat of approximately 6 for meaningful pain reduction [9]. Oral NSAIDs should not be used as stand-alone therapy for more than 2 weeks given the limited evidence for long-term tendon outcomes and known gastrointestinal and cardiovascular risks.

Step 3: Injection Therapies

Injections are not first-line. They are adjuncts when 8-12 weeks of supervised loading with or without ESWT has failed to produce adequate functional improvement.

Corticosteroid Injections: Short-Term Gain, Long-Term Risk

Corticosteroid injections (CSI) remain widely used despite a consistent evidence base showing short-term pain relief at 6 weeks followed by inferior outcomes at 6-12 months compared to exercise or even placebo injection. A systematic review by Coombes et al. In The Lancet (2010) analyzed 41 RCTs and found that while CSI was superior to other interventions at 6 weeks for lateral epicondylalgia, it was significantly worse at 26 weeks (success rate 69% for exercise vs. 54% for CSI, P<0.001) [10]. For Achilles tendinopathy, CSI carries an additional concern: a population-based cohort study by Movin et al. And subsequent analyses have associated peritendinous corticosteroid injection with increased risk of Achilles tendon rupture [11]. Imaging guidance (ultrasound) reduces the risk of intratendinous injection but does not eliminate the biological concerns.

Platelet-Rich Plasma

Platelet-rich plasma (PRP) delivers concentrated growth factors including PDGF, TGF-beta, and VEGF directly to the tendon. The clinical evidence is mixed across sites.

For patellar tendinopathy, a double-blind RCT by Dragoo et al. In the American Journal of Sports Medicine (N=23) found that PRP injection produced significantly greater improvements in VISA-P scores at 26 weeks compared to dry needling (P<0.05) [12]. A separate RCT by Filardo et al. (N=46) found comparable improvements between PRP and physical therapy at 12 months, suggesting PRP may accelerate early recovery without improving final outcomes [13].

For Achilles tendinopathy, a high-quality RCT by de Vos et al. In JAMA (N=54) found no statistically significant difference between PRP injection plus eccentric exercise and saline plus eccentric exercise on the VISA-A score at 24 weeks [14]. This remains the most-cited trial in the field.

The current evidence supports considering PRP for patellar tendinopathy after failure of 3 months of supervised loading, while Achilles tendinopathy data does not yet support PRP over structured rehabilitation alone.

Sclerosing Injections

Polidocanol sclerosing injections target neovascularization and associated nerve ingrowth in the tendon. A Swedish RCT by Alfredson and Öhberg (N=30) in the Knee Surgery, Sports Traumatology, Arthroscopy journal found that 5 injections of polidocanol reduced Achilles pain by 80% at 6 months compared to 22% in the lidocaine control group [15]. Patient selection matters: sclerosing therapy works best in patients with confirmed neovascularization on Doppler ultrasound.

Step 4: Off-Label and Emerging Therapies

The decision to move to off-label therapies should follow documented failure of Steps 1-3 over a minimum of 12 weeks, paired with a structured informed-consent discussion.

BPC-157: Evidence Status and Clinical Reality

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protein sequence. It is not FDA-approved for any indication. The evidence base for BPC-157 in tendon healing comes entirely from animal models. A 2010 study by Staresinic et al. Published in the Journal of Orthopaedic Research (rat Achilles model) showed accelerated tendon-to-bone healing and improved biomechanical strength in the BPC-157 group at 4 weeks [16]. No peer-reviewed human RCTs for BPC-157 in tendinopathy have been published as of this article's review date. Patients who ask about BPC-157 should be counseled that current evidence does not support its use outside of a clinical trial, and that compounded injectable peptides carry regulatory and safety uncertainties.

Prolotherapy and Hyaluronic Acid

Prolotherapy (dextrose injection) has modest RCT support for lateral epicondyle tendinopathy. A trial by Carayannopoulos et al. (N=24) found dextrose prolotherapy superior to corticosteroid at 1-year follow-up on the Patient-Rated Tennis Elbow Evaluation (PRTEE) score. Hyaluronic acid injections have shown some benefit in rotator cuff tendinopathy but evidence remains preliminary.

Rotator Cuff Tendinopathy: Site-Specific Considerations

Rotator cuff tendinopathy (supraspinatus most commonly) involves compressive load as well as tensile load, which modifies the rehabilitation approach. Compression against the coracoacromial arch during shoulder elevation means arc pain is often the presenting feature.

Exercise Selection

Rotator cuff loading programs emphasize external rotation and scapular stabilization exercises over pure eccentric protocols. A systematic review by Littlewood et al. In Manual Therapy found that self-managed loading programs produced outcomes equivalent to physiotherapist-supervised programs for rotator cuff tendinopathy, with effect sizes of 0.5-0.7 on pain and function scales [17].

Subacromial Injection Decisions

For patients with significant night pain and functional limitation, ultrasound-guided subacromial corticosteroid injection offers meaningful short-term relief. However, the British Elbow and Shoulder Society guidelines note that injections should not substitute for rehabilitation and should be limited to 2 per year given concerns about tendon tissue changes with repeated exposure [18].

Patellar Tendinopathy: The VISA-P Threshold for Escalation

Patellar tendinopathy is common in jumping athletes (volleyball, basketball) and frequently chronic. The VISA-P (Victorian Institute of Sport Assessment-Patella) questionnaire scores function on a 100-point scale. Scores below 50 at presentation suggest significant dysfunction and support earlier consideration of adjunctive treatment.

Progressive Tendon Loading Protocol

The Purdam decline squat protocol (25-degree decline board, single-leg squat, 3x15 twice daily for 12 weeks) is the standard eccentric program for patellar tendinopathy. A clinical trial by Purdam et al. In the British Journal of Sports Medicine (N=17) showed that decline squats produced greater pain reduction and VISA-P improvement than standard flat squats at 12 weeks (P<0.002) [19].

When VISA-P Scores Stall

If VISA-P scores fail to improve by at least 10 points after 12 weeks of supervised loading, re-imaging with ultrasound or MRI is warranted to exclude partial tear or bursitis before escalating to injection therapy.

A Practical Decision Framework for Clinicians

The following sequence reflects current evidence and HealthRX clinical protocols:

Weeks 1-4 (Reactive/Acute Phase)

• Relative load reduction (modify activity, not complete rest)
• Isometric exercise: 4-5 reps x 30-45 seconds, once daily
• Topical diclofenac for lateral epicondyle cases

Weeks 4-12 (Progressive Loading Phase)

• Eccentric or HSR protocol matched to anatomical site
• Add ESWT (3 sessions) if pain limits loading progression
• Re-assess at 8 weeks with validated outcome measure (VISA-A, VISA-P, PRTEE)

Week 12+ (Refractory Escalation)

• Imaging to confirm diagnosis and exclude partial tear
• Consider PRP for patellar tendinopathy or lateral epicondyle cases
• Consider ultrasound-guided CSI for rotator cuff cases with significant functional limitation (limit to 1-2 injections)
• Consider sclerosing injection if Doppler ultrasound confirms neovascularization

Week 24+ (Surgical Consultation)

• Refer for surgical assessment if structured conservative care has failed at 6 months and imaging confirms significant structural pathology

Return to Sport and Long-Term Outcomes

Return-to-sport timelines depend on the anatomical site and the severity of the loading deficit at presentation. A systematic review by Beyer et al. Found that 73% of patients with Achilles tendinopathy treated with HSR returned to their pre-injury sport level at 52 weeks [7]. Recurrence risk is reduced by maintaining a year-round tendon loading program at maintenance volume, even after symptoms resolve.

The British Journal of Sports Medicine's 2018 consensus statement on tendinopathy stated: "Rehabilitation of tendinopathy requires a minimum of 3 months of progressive loading for meaningful structural and clinical improvement, and athletes who discontinue loading on symptom resolution have a recurrence rate of up to 27% within 12 months" [20].

Patients with BMI <27 and no metabolic comorbidities tend to respond faster to loading protocols; metabolic contributors including diabetes, dyslipidemia, and fluoroquinolone use should be screened at first visit because each independently impairs tendon collagen synthesis.